XPhyto Therapeutics’ generic version of the Neupro patch for Parkinson’s disease is showing that its active ingredient, rotigotine, can be absorbed through the skin in ways similar to the brand-name product, the company announced. Findings, in work using skin from human cadavers and an optimized formula for the generic patch, support…
REM sleep behavior disorder (RBD) and autonomic dysfunction (dysautonomia), two types of nonmotor Parkinson’s disease symptoms, were significant predictors of anxiety in Parkinson’s patients over a three-year study. More than half (57%) of patients in in the study met the clinical criteria for anxiety at some point, underscoring its…
Four weeks of physical therapy — specifically, the Lee Silverman Voice Therapy (LSVT)-BIG program — given via telemedicine led to improvements in life quality and symptoms in Parkinson’s disease patients similar to those observed with in-person use of LSVT-BIG, according to a small study. Larger studies of the virtual exercise…
People with persistent smell deficits are more likely to develop brain imaging abnormalities suggestive of Parkinson’s disease, or be diagnosed with the disease, than those whose deficits return to normal on a subsequent smell test, according to data from a Phase 2 study. Deficits in two consecutive smell tests,…
Scientists have shed new light on the interaction of toxic apha-synuclein clumps — a hallmark of Parkinson’s disease — with microglia, the brain’s immune cells. This interaction was found to be mediated by RAGE, a protein at the surface of microglia, which promoted the release of inflammatory molecules from…
GT-02287, Gain Therapeutics’ experimental oral therapy, reduced the toxic alpha-synuclein protein clumps that characterize Parkinson’s disease in lab-grown nerve cells derived from patients with disease-causing mutations in the GBA1 gene, the company announced. The treatment also boosted the function of lysosomes, the cells’ recycling centers, which is…
Researchers have developed a test that may help to more accurately diagnose Parkinson’s disease and monitor its progression. It combines two already-used laboratory techniques to measure clumps of alpha-synuclein in the cerebrospinal fluid (CSF). Alpha-synuclein is the protein that progressively builds to toxic levels in the brain and…
The hormone irisin prevents the buildup of toxic alpha-synuclein protein, leading to the preservation of nerve cells and easing motor symptoms in a mouse model of Parkinson’s disease, a study has found. Experiments showed the hormone had an ability to facilitate the breakdown of toxic alpha-synuclein through lysosomes, the…
Exercise can modify the connectivity of the brain’s pedunculopontine nucleus (PPN) with other areas of the brain in people with Parkinson’s disease and gait impairments, a study has found. Decreases in connectivity of the PPN on the left side of the brain after exercise were associated with motor improvements…
Enrollment is now complete for a Phase 2 trial of NYX-458, Aptinyx’s investigational therapy to treat cognitive impairment in people with Parkinson’s disease. After a pause in enrollment due to the COVID-19 pandemic, the trial resumed enrolling in April 2021. Now, a total of 99 adults, ages…
Get regular updates to your inbox.
